Targeting FOLR1 for treating progressive inflammatory lung disorders such as COPD
Implementing Organization
Principal Investigator
Dr. Bijesh P
CSIR-Indian Institute Of Chemical Biology (CSIR–IICB), West Bengal
About
Chronic obstructive pulmonary disease (COPD) affects over 65 million people worldwide, making it the third leading cause of death. To treat COPD and related lung disorders, understanding inflammatory responses and drugs targeting progressive apoptosis pathways in lung epithelial cells is crucial. Folates, vitamins B9 involved in one-carbon metabolism, have limited conversion efficiency in humans into biological derivatives. Most folate in organisms exists as 5-methyltetrahydrofolate. A preliminary study on BEAS-2B cells revealed that biological folate derivatives protect cells from oxidative stress, with 5-methyltetrahydrofolate and 10-formyltetrahydrofolate showing higher cytoprotective activity compared to synthetic folic acid. The study also revealed that reactive oxygen species scavenging activity of the folate derivatives was evident. Inflammatory markers such as NF-kB, IL6, TNF-α, and MCP-1 were suppressed after supplementation with biological folate derivatives. FOLR1, an active folate transporter, is involved in the movement of folate across cell membranes. The lung expresses the highest rate of the active folate transporter, FLOR1, among human organs. FOLR1 is highest expressed in alveolar epithelial type 2 cells (AEC2), which are critical for maintaining lung homeostasis and repair and regeneration. Restoration of lung health relies heavily on protecting AEC2 cells and promoting cell division. Analysis of FOLR1 in BEAS-2B cells shows upregulation under smoke-induced stress, suggesting the rapid depletion of intracellular folate due to reactive oxygen species. Intranasal application of folate derivatives can assure the supply of folate to lung epithelial cells, providing better antioxidant and antiinflammatory activity.
Source
Source
Anusandhan National Research Foundation/Science and Engineering Research Board (SERB), DST 2023-24
Science and Engineering Research Board (SERB), New Delhi
Anusandhan National Research Foundation (ANRF)
Quick Information
Area of Research
Medical Sciences
Focus Area
Immunology
Start Year
2023
End Year
2025
Sanction Amount
₹ 30.57 L
Status
Completed
Contact
bputhusseri@iicb.res.in
Output
No. of Research Paper
00
Technologies (If Any)
00
No. of PhD Produced
00
No. of Patents
Filed :00
Grant :00
Disclaimer:
Information available on this portal is sourced from various organizations and is provided for informational purposes only. Users are advised to verify details from the respective official sources.
Please enter your details
Please provide your name and email to continue. Your details are saved in this browser for future use.
Latest Updates
Loading…
⚠️
You are leaving this website
You are about to be redirected to an external website that is not operated by
India Science, Technology & Innovation (ISTI) Portal.